Log in
NYSE:CRY

CryoLife Competitors

$20.87
+0.83 (+4.14 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$19.93
Now: $20.87
$20.88
50-Day Range
$16.76
MA: $18.92
$20.93
52-Week Range
$12.63
Now: $20.87
$31.77
Volume122,149 shs
Average Volume298,448 shs
Market Capitalization$810.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37

Competitors

CryoLife (NYSE:CRY) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying CRY stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to CryoLife, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

CryoLife (NYSE:CRY) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CryoLife and Abbott Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CryoLife01402.80
Abbott Laboratories141302.67

CryoLife currently has a consensus target price of $27.25, suggesting a potential upside of 30.57%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given CryoLife's stronger consensus rating and higher probable upside, analysts plainly believe CryoLife is more favorable than Abbott Laboratories.

Earnings and Valuation

This table compares CryoLife and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CryoLife$276.22 million2.94$1.72 million$0.3167.32
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than CryoLife. Abbott Laboratories is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CryoLife and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryoLife-5.45%1.86%0.82%
Abbott Laboratories10.50%18.19%8.29%

Volatility & Risk

CryoLife has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

Insider and Institutional Ownership

74.7% of CryoLife shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 4.7% of CryoLife shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abbott Laboratories beats CryoLife on 9 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and CryoLife (NYSE:CRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Medtronic and CryoLife, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
CryoLife01402.80

Medtronic presently has a consensus price target of $118.1538, indicating a potential upside of 6.47%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's higher probable upside, analysts plainly believe CryoLife is more favorable than Medtronic.

Valuation & Earnings

This table compares Medtronic and CryoLife's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
CryoLife$276.22 million2.94$1.72 million$0.3167.32

Medtronic has higher revenue and earnings than CryoLife. Medtronic is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
CryoLife-5.45%1.86%0.82%

Volatility and Risk

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 4.7% of CryoLife shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats CryoLife on 12 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and CryoLife (NYSE:CRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Stryker and CryoLife, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
CryoLife01402.80

Stryker presently has a consensus price target of $221.44, indicating a potential downside of 4.97%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher probable upside, analysts plainly believe CryoLife is more favorable than Stryker.

Valuation & Earnings

This table compares Stryker and CryoLife's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
CryoLife$276.22 million2.94$1.72 million$0.3167.32

Stryker has higher revenue and earnings than CryoLife. Stryker is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
CryoLife-5.45%1.86%0.82%

Volatility and Risk

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 4.7% of CryoLife shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Stryker beats CryoLife on 11 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and CryoLife (NYSE:CRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Intuitive Surgical and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
CryoLife-5.45%1.86%0.82%

Insider and Institutional Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and CryoLife's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
CryoLife$276.22 million2.94$1.72 million$0.3167.32

Intuitive Surgical has higher revenue and earnings than CryoLife. CryoLife is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Intuitive Surgical and CryoLife, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
CryoLife01402.80

Intuitive Surgical presently has a consensus price target of $718.2778, indicating a potential downside of 0.11%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher possible upside, analysts plainly believe CryoLife is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats CryoLife on 10 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and CryoLife (NYSE:CRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Becton, Dickinson and and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
CryoLife-5.45%1.86%0.82%

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Valuation and Earnings

This table compares Becton, Dickinson and and CryoLife's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40
CryoLife$276.22 million2.94$1.72 million$0.3167.32

Becton, Dickinson and has higher revenue and earnings than CryoLife. Becton, Dickinson and is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Becton, Dickinson and and CryoLife, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
CryoLife01402.80

Becton, Dickinson and presently has a consensus price target of $280.2857, indicating a potential upside of 22.67%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher possible upside, analysts plainly believe CryoLife is more favorable than Becton, Dickinson and.

Summary

Becton, Dickinson and beats CryoLife on 10 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and CryoLife (NYSE:CRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Edwards Lifesciences and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
CryoLife-5.45%1.86%0.82%

Insider and Institutional Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Valuation and Earnings

This table compares Edwards Lifesciences and CryoLife's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54
CryoLife$276.22 million2.94$1.72 million$0.3167.32

Edwards Lifesciences has higher revenue and earnings than CryoLife. Edwards Lifesciences is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Edwards Lifesciences and CryoLife, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
CryoLife01402.80

Edwards Lifesciences presently has a consensus price target of $87.7222, indicating a potential upside of 3.57%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher possible upside, analysts plainly believe CryoLife is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats CryoLife on 10 of the 14 factors compared between the two stocks.


CryoLife Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.